{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T04:40:07Z","timestamp":1756096807026,"version":"3.44.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0210113","JP25fk0210174"],"award-info":[{"award-number":["JP24fk0210113","JP25fk0210174"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00535-025-02275-3","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:14:20Z","timestamp":1750418060000},"page":"1145-1156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis"],"prefix":"10.1007","volume":"60","author":[{"given":"Naoki","family":"Kawagishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-9106","authenticated-orcid":false,"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Mawatari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekatsu","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisamitsu","family":"Miyaaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kakazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"2275_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","volume":"402","author":"M Martinello","year":"2023","unstructured":"Martinello M, Solomon SS, Terrault NA, et al. Hepatitis C. Lancet. 2023;402:1085\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(23)01320-X.","journal-title":"Lancet"},{"key":"2275_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/hepr.12331","volume":"45","author":"Y Tachi","year":"2015","unstructured":"Tachi Y, Hirai T, Miyata A, et al. Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res. 2015;45:238\u201346. https:\/\/doi.org\/10.1111\/hepr.12331.","journal-title":"Hepatol Res"},{"key":"2275_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","volume":"132","author":"Y Shiratori","year":"2000","unstructured":"Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517\u201324. https:\/\/doi.org\/10.7326\/0003-4819-132-7-200004040-00002.","journal-title":"Ann Intern Med"},{"key":"2275_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/hepr.13490","volume":"50","author":"N Kawagishi","year":"2020","unstructured":"Kawagishi N, Suda G, Kimura M, et al. High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. Hepatol Res. 2020;50:671\u201381. https:\/\/doi.org\/10.1111\/hepr.13490.","journal-title":"Hepatol Res"},{"key":"2275_CR5","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/hep.29557","volume":"67","author":"E Mauro","year":"2018","unstructured":"Mauro E, Crespo G, Montironi C, et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology. 2018;67:1683\u201394. https:\/\/doi.org\/10.1002\/hep.29557.","journal-title":"Hepatology"},{"key":"2275_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/v15010181","author":"N Kawagishi","year":"2023","unstructured":"Kawagishi N, Suda G, Yamamoto Y, et al. Serum angiopoietin-2 predicts the occurrence and recurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15010181.","journal-title":"Viruses"},{"key":"2275_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. Electronic address, clinical practice guidelines panel C, representative EGB, et al. EASL recommendations on treatment of hepatitis C: final update of the series(\u2606). J Hepatol. 2020;73:1170\u2013218. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.018.","journal-title":"J Hepatol."},{"key":"2275_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","volume":"73","author":"EC Verna","year":"2020","unstructured":"Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020;73:540\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.031.","journal-title":"J Hepatol"},{"key":"2275_CR9","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00535-023-02039-x","volume":"58","author":"Y Tahata","year":"2023","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus. J Gastroenterol. 2023;58:1211\u201321. https:\/\/doi.org\/10.1007\/s00535-023-02039-x.","journal-title":"J Gastroenterol"},{"key":"2275_CR10","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1073\/pnas.1714446115","volume":"115","author":"T Souma","year":"2018","unstructured":"Souma T, Thomson BR, Heinen S, et al. Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP. Proc Natl Acad Sci U S A. 2018;115:1298\u2013303. https:\/\/doi.org\/10.1073\/pnas.1714446115.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2275_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070459","volume":"8","author":"AV Benest","year":"2013","unstructured":"Benest AV, Kruse K, Savant S, et al. Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS ONE. 2013;8: e70459. https:\/\/doi.org\/10.1371\/journal.pone.0070459.","journal-title":"PLoS ONE"},{"key":"2275_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov. 2017;16:635\u201361. https:\/\/doi.org\/10.1038\/nrd.2016.278.","journal-title":"Nat Rev Drug Discov"},{"key":"2275_CR13","doi-asserted-by":"publisher","first-page":"9207","DOI":"10.1038\/s41598-021-88632-7","volume":"11","author":"N Kawagishi","year":"2021","unstructured":"Kawagishi N, Suda G, Kimura M, et al. Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Sci Rep. 2021;11:9207. https:\/\/doi.org\/10.1038\/s41598-021-88632-7.","journal-title":"Sci Rep"},{"key":"2275_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.30230","volume":"69","author":"AS Allegretti","year":"2019","unstructured":"Allegretti AS, Vela Parada X, Ortiz GA, et al. Serum angiopoietin-2 predicts mortality and kidney outcomes in decompensated cirrhosis. Hepatology. 2019;69:729\u201341. https:\/\/doi.org\/10.1002\/hep.30230.","journal-title":"Hepatology"},{"key":"2275_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00535-020-01733-4","volume":"56","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67\u201377. https:\/\/doi.org\/10.1007\/s00535-020-01733-4.","journal-title":"J Gastroenterol"},{"key":"2275_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00535-021-01845-5","volume":"57","author":"Y Tahata","year":"2022","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022;57:120\u201332. https:\/\/doi.org\/10.1007\/s00535-021-01845-5.","journal-title":"J Gastroenterol"},{"key":"2275_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14131","author":"Y Tahata","year":"2024","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy. Hepatol Res. 2024. https:\/\/doi.org\/10.1111\/hepr.14131.","journal-title":"Hepatol Res"},{"key":"2275_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/hepr.13503","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines tJSoH","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines tJSoH. Japan society of hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020;50:791\u2013816. https:\/\/doi.org\/10.1111\/hepr.13503.","journal-title":"Hepatol Res"},{"key":"2275_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jcp.21229","volume":"214","author":"W Goettsch","year":"2008","unstructured":"Goettsch W, Gryczka C, Korff T, et al. Flow-dependent regulation of angiopoietin-2. J Cell Physiol. 2008;214:491\u2013503. https:\/\/doi.org\/10.1002\/jcp.21229.","journal-title":"J Cell Physiol"},{"key":"2275_CR20","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/hep.29911","volume":"68","author":"F Faillaci","year":"2018","unstructured":"Faillaci F, Marzi L, Critelli R, et al. Liver Angiopoietin-2 Is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals. Hepatology. 2018;68:1010\u201324. https:\/\/doi.org\/10.1002\/hep.29911.","journal-title":"Hepatology"},{"key":"2275_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/hep.30885","volume":"71","author":"M Mandorfer","year":"2020","unstructured":"Mandorfer M, Kozbial K, Schwabl P, et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology. 2020;71:1023\u201336. https:\/\/doi.org\/10.1002\/hep.30885.","journal-title":"Hepatology"},{"key":"2275_CR22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/hepr.13823","volume":"52","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Matsuura K, Nagura Y, et al. Serum angiopoietin-2 levels predict regression of Mac-2 binding protein glycosylation isomer-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents. Hepatol Res. 2022;52:919\u201327. https:\/\/doi.org\/10.1111\/hepr.13823.","journal-title":"Hepatol Res"},{"key":"2275_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/gut.2008.155028","volume":"58","author":"P Melgar-Lesmes","year":"2009","unstructured":"Melgar-Lesmes P, Tugues S, Ros J, et al. Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats. Gut. 2009;58:285\u201392. https:\/\/doi.org\/10.1136\/gut.2008.155028.","journal-title":"Gut"},{"key":"2275_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/liv.12505","volume":"35","author":"M Pauta","year":"2015","unstructured":"Pauta M, Ribera J, Melgar-Lesmes P, et al. Overexpression of angiopoietin-2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver Int. 2015;35:1383\u201392. https:\/\/doi.org\/10.1111\/liv.12505.","journal-title":"Liver Int."},{"key":"2275_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155\u201370. https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.023.","journal-title":"Ophthalmology"},{"key":"2275_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.2022.40.4_suppl.434","volume":"40","author":"T Meyer","year":"2022","unstructured":"Meyer T, Ledin E, Kim D-W, et al. Phase Ib study of BI 836880 (VEGF\/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2022;40:434. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.434.","journal-title":"J Clin Oncol"},{"key":"2275_CR27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/hep.30294","volume":"69","author":"S Lefere","year":"2019","unstructured":"Lefere S, Van de Velde F, Hoorens A, et al. Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine non-alcoholic fatty liver disease. Hepatology. 2019;69:1087\u2013104. https:\/\/doi.org\/10.1002\/hep.30294.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02275-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02275-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02275-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T04:04:02Z","timestamp":1756094642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02275-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02275-3","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Satoshi Mochida received lecture fees from Gilead Sciences, Inc., AbbVie GK., ASKA Pharmaceutical Co., Ltd., Toray Industries Inc., Otsuka Pharmaceutical Co., Ltd., and Eisai Co., Ltd. Takahiro Kodama received lecture fees from AbbVie GK. and Gilead Sciences, Inc. Masayuki Kurosaki received lecture fees from Gilead, AbbVie, Eisai, Chugai, AstraZeneca, Lilly, and Takeda. Yoichi Hiasa received lecture fees from AbbVie GK. and Gilead Sciences, Inc. Norifumi Kawada received research grants from AstraZeneca plc., Bristol Myers Squibb., GlaxoSmithKline plc., MSD co., ltd., Gilead Sciences, Inc., and Novo Nordisk Pharma Ltd.; scholarship grants from AbbVie GK, Eisai Co., Ltd., and Otsuka Pharmaceutical Co.; and lecture fees from AbbVie GK, Gilead Sciences, Inc., and MSD Co., Ltd. Goki Suda received research grants from Gilead Sciences, Inc. Hitoshi Yoshiji received lecture fees from Gilead Sciences Inc. Naoya Kato received research grants from AbbVie G.K., scholarship grants from Gilead Sciences, Inc., and lecture fees from Gilead Sciences, Inc. and AbbVie G.K. Taro Takami received lecture fees from Gilead Sciences, Inc. Yoshito Itoh received scholarship grants from AbbVie Inc., lecture fees from AbbVie Inc. and Gilead Sciences Inc. Shuji Terai received lecture fees from Otsuka, AbbVie, Asuka, Daiichi Sankyo, Chiomu Takedansen, and Gilead Sciences, Inc. Yoshiyuki Ueno received lecture fees from AbbVie Inc. Norio Akuta received lecture fees from AbbVie Inc. Naoya Sakamoto received lecture fees from Chugai Pharmaceutical Co., Ltd. and research grants from Gilead Sciences, Inc. and AbbVie, Inc. Tetsuo Takehara received research grants and lecture fees from AbbVie GK. and Gilead Sciences, Inc. All other authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}